Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CMLZhu G. · Ji O. · Ji J. · Zhang Y. · Wu Y. · Yu H. · Jiang P.-J. · Shen Q.
aDepartment of Hematology, First Affiliated Hospital of Nanjing University of Chinese Medicine, and bFirst Clinical College Department, Nanjing University of Chinese Medicine, Nanjing, China
Imatinib resistance is an important hurdle in the treatment of chronic myeloid leukemia (CML), and CML patients with this drug resistance are often given a dismal prognosis. In this case report, an imatinib-refractory blast phase CML patient was treated with a combination of imatinib and nilotinib. A complete hematologic response was achieved within 3 months, the drug combination was well tolerated, and there was a relatively long bone-marrow complete remission. These results suggest that combining imatinib and nilotinib treatment may improve the outcome of imatinib-resistant CML patients in the blast phase. We hypothesize regarding the possible mechanism for the effectiveness of the drug combination by reviewing the recent literature.
Qun Shen, PhD
Department of Hematology, First Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road
Nanjing 210029 (China)
Tel. +86 258 605 9194, E-Mail email@example.com
Received : May 23, 2011
Accepted after revision : August 22, 2011
Published online: January 27, 2012
Number of Print Pages : 4
Number of Figures : 2, Number of Tables : 0, Number of References : 8
Vol. 127, No. 3, Year 2012 (Cover Date: March 2012)
Journal Editor: Ben-Bassat I. (Qiryat-Ono)
ISSN: 0001-5792 (Print), eISSN: 1421-9662 (Online)
For additional information: http://www.karger.com/AHA